TSCAN THERAPEUTICS, INC. (TCRX) Free cash flow 2020–2025
TSCAN THERAPEUTICS, INC. (TCRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$139.7MFY2025 · since FY2020: -$7.3M → -$139.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$139.7M | -21.9% |
| FY2024 | -$114.6M | -77.7% |
| FY2023 | -$64.5M | +8.8% |
| FY2022 | -$70.7M | -20.7% |
| FY2021 | -$58.6M | -707.3% |
| FY2020 | -$7.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRX financial trends
TCRX RevenueTCRX Net incomeTCRX Net marginTCRX Gross profitTCRX Gross marginTCRX Operating incomeTCRX Operating marginTCRX Operating cash flowTCRX Capital expendituresTCRX Return on equityTCRX Stock buybacksTCRX Dividends paidTCRX Total assetsTCRX Total liabilitiesTCRX Shareholders’ equityTCRX overview →